Israeli Study Links GLP-1 Drugs to Rare Brain Disorder

Israeli Study Links GLP-1 Drugs to Rare Brain Disorder

Health

Israeli researchers identified 15 cases of Wernicke encephalopathy among users of GLP-1 weight-loss drugs in Israel, prompting calls for further investigation. Earlier reports noted that the study, which examined nearly 196,000 patients, found the cases were disproportionately linked to semaglutide and tirzepatide, highlighting a risk of severe vitamin-B1 deficiency.

Actors

Israeli researchers semaglutide tirzepatide

Locations

Israel

Fact Check

How these metrics work
Verdict: Insufficient evidence Confidence: 22% Claims: 3
At a glance

All three claims stating that researchers or reviews identified 15 cases of Wernicke encephalopathy associated with GLP-1 receptor agonists, including semaglutide and tirzepatide, between September 11 and 13, 2026, have insufficient evidence.

Sign in or subscribe to unlock the full breakdown: claims, sources, and validations.

Sign up Sign in

This section contains an automated verification of claims against external sources and may contain inaccuracies.

Articles

September 15, 2026
1 total
Study links GLP-1 weight-loss drugs to rare cases of Wernicke encephalopathy
Study links GLP-1 weight-loss drugs to rare cases of Wernicke encephalopathy

The Independent • 15 Sep 17:45

An Israeli review of FDA adverse-event reports identified 15 instances of Wernicke encephalopathy among users of GLP-1 medications, prompting calls for further investigation.

Credibility 71% Manip. 9% Center
September 13, 2026
2 total
Study links GLP-1 weight-loss drugs to rare vitamin B1 deficiency disorder
Study links GLP-1 weight-loss drugs to rare vitamin B1 deficiency disorder

Fox News • 13 Sep 17:00

A review of FDA reports and medical literature identified 15 cases of Wernicke encephalopathy among users of semaglutide and tirzepatide, prompting calls for further research.

Credibility 68% Manip. 30% Center
Study links GLP-1 weight-loss drugs to rare cases of Wernicke encephalopathy
Study links GLP-1 weight-loss drugs to rare cases of Wernicke encephalopathy

Yahoo Health • 13 Sep 17:00

Researchers identified 15 reports of Wernicke encephalopathy in patients using GLP-1 receptor agonists, highlighting a possible link to vitamin B1 deficiency but noting the rarity of the condition.

Credibility 68% Manip. 12% Center
September 12, 2026
1 total
Study links GLP-1 weight-loss drugs to rare vitamin B1 deficiency causing Wernicke encephalopathy
Study links GLP-1 weight-loss drugs to rare vitamin B1 deficiency causing Wernicke encephalopathy

NewsNation • 12 Sep 20:18

Researchers identified 15 cases of Wernicke encephalopathy in 2023-2024 among patients using GLP-1 agonists, highlighting a potential risk of severe thiamine deficiency.

Credibility 72% Manip. 8% Center
September 11, 2026
1 total
Study links two GLP-1 weight-loss drugs to rare brain disorder
Study links two GLP-1 weight-loss drugs to rare brain disorder

New York Post • 11 Sep 16:09

Research involving nearly 196,000 patients identified 15 cases of Wernicke encephalopathy, a serious condition linked to vitamin B1 deficiency, that were disproportionately associated with semaglutide and tirzepatide.

Credibility 57% Manip. 27% Center

Related events